|
||||||
|
 | |
| |
| Expression of this gene in the resistant group across all datasets and cell types |
| |
| |
| |
| |
| Acts as a transcription factor (This gene does not contain this module) |
|
Gene: IL1B |
Summary for IL1B |
| Gene information | Gene symbol | IL1B | Ensembl ID | ENSG00000125538 |
| Entrez ID | 3553 | |
| Gene name | interleukin 1 beta | |
| Synonyms | IL-1B|IL1-BETA|IL1F2 | |
| Gene type | protein_coding | |
| UniProtAcc | P01584 |
Top |
Dataset with differentially expressed gene: IL1B |
 Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group. |
| Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE140440 | DU145 and PCÂ cell lines | Cell line | Prostate cancer | Prostate cancer | Chemotherapy | docetaxel | NA | Malignant cells | 5.74131 | 9.75e-07 |
GSE169246_PacBlood | patients | Peripheral blood mononuclear cells | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | post | Mono/Macro | -0.435044 | 0.00e+00 |
GSE169246_PacTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Chemotherapy | paclitaxel | pre | Mono/Macro | -1.08807 | 0.00e+00 |
GSE169246_PacAteTissue | patients | Tumor tissue | Breast cancer | Advanced triple-negative breast cancer (TNBC) | Immunotherapy | atezolizumab + paclitaxel | pre | Mono/Macro | -0.417767 | 2.64e-08 |
GSE164551 | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Immunotherapy | CAR-T | NA | Mono/Macro | -0.398403 | 1.88e-06 |
GSE197268_Tisa-cel | patients | Peripheral blood mononuclear cells | Acute lymphoblastic leukemia | Large B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | tisa-cel (CAR-T) | post | Mono/Macro | -0.295799 | 0.00e+00 |
GSE207422_Tor | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Neutrophils | 1.20784 | 2.23e-12 |
GSE207422_Tor | patients | Tumor tissue | Lung cancer | EGFR/ALK mutation negative non-small cell lung cancer (NSCLC) | Immunotherapy | toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine) | post | Mono/Macro | 1.09582 | 7.63e-06 |
GSE189460 | patients | Bone marrow aspirate | Multiple myeloma | Multiple myeloma (MM) | Targeted therapy | bortezomib + melphalan + prednisolone | pre | Mono/Macro | -0.973791 | 9.98e-25 |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | pre | Mono/Macro | 2.0014 | 0.00e+00 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post | Malignant cells | -0.701277 | 0.00e+00 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post | cDCs | -0.336379 | 4.52e-10 |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | pre | Malignant cells | -0.411788 | 0.00e+00 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | post | Mono/Macro | -0.931175 | 0.00e+00 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | Mono/Macro | -0.634729 | 7.14e-26 |
GSE164897_Vem | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib | NA | Malignant cells | 0.283774 | 0.00e+00 |
Top |
Expression of IL1B in the resistant group across all datasets and cell types |
| Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.) |
 |
Top |
Significant ligand-receptor pairs related to IL1B |
| This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.) |
| Gene symbol | Cell type with DEG | Interaction ID | Interacting pair | Gene A | Gene B | Integrin | Interacting cell type1 | Interacting cell type2 | Dataset | Timepoint | Condition |
| IL1B | Mono/Macro | CPI-SC01BC018A0 | IL1B_IL1_receptor_inhibitor | IL1B | NA | False | Mono/Macro | Mono/Macro | GSE164551 | NA | sensitive |
| IL1B | Mono/Macro | CPI-SC0D5A18C2E | IL1B_IL1_receptor | IL1B | NA | False | Mono/Macro | Mono/Macro | GSE164551 | NA | sensitive |
| IL1B | Mono/Macro | CPI-SC01BC018A0 | IL1B_IL1_receptor_inhibitor | IL1B | NA | False | Mono/Macro | Mono/Macro | GSE197268_Tisa-cel | post | resistant |
| IL1B | Mono/Macro | CPI-SC01BC018A0 | IL1B_IL1_receptor_inhibitor | IL1B | NA | False | Mono/Macro | Mono/Macro | GSE197268_Tisa-cel | post | sensitive |
| IL1B | Neutrophils | CPI-SC01BC018A0 | IL1B_IL1_receptor_inhibitor | IL1B | NA | False | Mono/Macro | Neutrophils | GSE207422_Tor | post | resistant |
| IL1B | Neutrophils | CPI-SC01BC018A0 | IL1B_IL1_receptor_inhibitor | IL1B | NA | False | Neutrophils | Neutrophils | GSE207422_Tor | post | resistant |
| IL1B | Mono/Macro | CPI-SC01BC018A0 | IL1B_IL1_receptor_inhibitor | IL1B | NA | False | Mono/Macro | Neutrophils | GSE207422_Tor | post | resistant |
| IL1B | Neutrophils | CPI-SC0D5A18C2E | IL1B_IL1_receptor | IL1B | NA | False | Neutrophils | Fibroblasts | GSE207422_Tor | post | sensitive |
| IL1B | Mono/Macro | CPI-SC0D5A18C2E | IL1B_IL1_receptor | IL1B | NA | False | Mono/Macro | Fibroblasts | GSE207422_Tor | post | sensitive |
| Page: 1 |
Top |
Known drug resistance mechanisms of this gene |
| This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information. |
| Gene symbol | Mechanism |
IL1B | Aberration of the Drug's Therapeutic Target |
IL1B | Regulation by the Disease Microenvironment |
IL1B | Unusual Activation of Pro-survival Pathway |
| Page: 1 |
Top |
MicroRNAs (miRNA) regulating IL1B |
| This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.) |
| Gene symbol | miRNA | Score | GeneBank accession |
| IL1B | hsa-miR-5692a | 99.1186 | NM_000576 |
| IL1B | hsa-miR-5688 | 97.2651 | NM_000576 |
| IL1B | hsa-miR-495-3p | 97.2651 | NM_000576 |
| IL1B | hsa-miR-1291 | 89.196 | NM_000576 |
| IL1B | hsa-miR-6775-3p | 86.8362 | NM_000576 |
| IL1B | hsa-miR-4729 | 85.3312 | NM_000576 |
| IL1B | hsa-miR-3147 | 83.3163 | NM_000576 |
| IL1B | hsa-miR-30d-3p | 82.7221 | NM_000576 |
| IL1B | hsa-miR-30e-3p | 82.7221 | NM_000576 |
| IL1B | hsa-miR-30a-3p | 82.7221 | NM_000576 |
| IL1B | hsa-miR-4276 | 82.2068 | NM_000576 |
| IL1B | hsa-miR-4313 | 81.0902 | NM_000576 |
| Page: 1 |
Top |
Motifs and transcription factors (TFs) regulating IL1B |
| This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.) |
| Gene symbol | motif | TF_highConf |
| IL1B | transfac_pro__M05667 | ZNF35 (directAnnotation). |
| IL1B | tfdimers__MD00218 | ATF1; ATF2; ATF3; ATF4; ATF7; CREB1; CREM; ELF1 (directAnnotation). |
| IL1B | metacluster_53.2 | ZNF8 (directAnnotation). |
| IL1B | homer__GGAAATTCCC_NFkB-p65-Rel | RELA (inferredBy_Orthology). |
| IL1B | taipale_tf_pairs__ELK1_FOXI1_RSCGGAANNRTMAAYA_CAP_repr | ELK1; FOXI1 (directAnnotation). |
| IL1B | metacluster_22.27 | NFE2L2 (inferredBy_Orthology). |
| IL1B | kznf__ZFP1_Isakova2017.1_SMiLE-seq | ZFP1 (directAnnotation). |
| IL1B | transfac_pro__M05967 | ZFP30 (directAnnotation). |
| IL1B | metacluster_172.6 | CHD2; E2F1 (directAnnotation). |
| IL1B | tfdimers__MD00066 | ELF1 (directAnnotation). |
| IL1B | taipale_tf_pairs__MGA_DLX3_AGGTGNTAATKR_CAP | DLX3; MGA (directAnnotation). |
| IL1B | dbtfbs__ZNF660_HEK293_ENCSR283DOU_merged_N1 | ZNF660 (directAnnotation). |
| IL1B | transfac_pro__M00655 | ETV4 (directAnnotation). |
| IL1B | transfac_pro__M06130 | ZNF254 (directAnnotation). |
| IL1B | transfac_pro__M05707 | ZNF239 (inferredBy_Orthology). |
| IL1B | hocomoco__HSF1_MOUSE.H11MO.1.A | HSF1 (inferredBy_Orthology). |
| IL1B | taipale_tf_pairs__MGA_DLX2_SYAATTANWGGTGYGA_CAP | DLX2; MGA (directAnnotation). |
| IL1B | taipale_tf_pairs__TEAD4_ETV4_RCCGGAAATRCC_CAP | ETV4; TEAD4 (directAnnotation). |
| IL1B | transfac_pro__M05350 | ZNF146 (directAnnotation). |
| IL1B | transfac_pro__M06317 | ZNF829 (directAnnotation). |
| IL1B | transfac_pro__M05815 | ZNF613 (directAnnotation). |
| IL1B | metacluster_172.22 | E4F1 (inferredBy_Orthology). |
| IL1B | taipale_tf_pairs__TEAD4_PITX1_RCATWCYNNNNTAATCC_CAP_repr | PITX1; TEAD4 (directAnnotation). |
| IL1B | kznf__ZNF791_Imbeault2017_RP_ChIP-seq | ZNF791 (directAnnotation). |
| IL1B | taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr | CREB1 (directAnnotation). |
| IL1B | transfac_pro__M06325 | ZNF585A (directAnnotation). |
| IL1B | metacluster_47.1 | E4F1; SPDEF; SPDEF (directAnnotation). |
| IL1B | metacluster_130.3 | ZNF492; ZNF492 (directAnnotation). OVOL2; OVOL3; PEG3; PLAG1; PLAGL1; PLAGL2; REST; SCAND1; ZKSCAN2; ZNF131; ZNF174; ZNF18; ZNF202; ZNF274; ZNF444; ZNF446; ZNF496; ZNF518A; ZNF518B; ZNF576; ZNF641; ZNF770; ZSCAN1; ZSCAN18; ZSCAN29; ZSCAN32; ZSCAN5A; ZSCAN5B; ZSCAN5C (inferredBy_Orthology). |
| IL1B | metacluster_22.33 | MAFK (inferredBy_Orthology). |
| IL1B | jaspar__MA1125.1 | ZNF384 (directAnnotation). |
| IL1B | transfac_pro__M06157 | ZNF445 (directAnnotation). |
| IL1B | metacluster_22.7 | MAFK (directAnnotation). |
| IL1B | transfac_pro__M05451 | ZNF541 (directAnnotation). |
| IL1B | transfac_pro__M05984 | ZNF586 (directAnnotation). |
| IL1B | metacluster_22.8 | MAF; MAFA; MAFF; MAFF; MAFG (directAnnotation). |
| IL1B | tfdimers__MD00027 | FOXG1; FOXO1; HLTF (directAnnotation). |
| IL1B | metacluster_22.2 | MAFK (directAnnotation). |
| IL1B | taipale_tf_pairs__ETV7_TBX21_NSCGGAARNNNNNNTCACACNN_CAP_repr | ETV7; TBX21 (directAnnotation). |
| IL1B | metacluster_167.7 | IRF8 (inferredBy_Orthology). |
| IL1B | transfac_pro__M05304 | ZBTB5 (directAnnotation). |
| IL1B | kznf__CTCF_Rhee2011.3_ChIP-exo | CTCF (directAnnotation). |
| IL1B | transfac_pro__M04886 | ETS1 (directAnnotation). |
| IL1B | swissregulon__hs__DBP | DBP (directAnnotation). |
| IL1B | taipale_tf_pairs__ELK1_PAX1_RSCGGAACYACGCWYSANTG_CAP | ELK1; PAX1 (directAnnotation). |
| IL1B | taipale_tf_pairs__ETV2_SPDEF_NSCGGACGGAWATCCGSNT_CAP | ETV2; SPDEF (directAnnotation). |
| IL1B | transfac_pro__M06800 | ZBTB22 (inferredBy_Orthology). |
| IL1B | transfac_pro__M06688 | ZKSCAN7 (directAnnotation). |
| IL1B | transfac_pro__M06750 | ZNF510 (directAnnotation). |
| IL1B | transfac_pro__M05352 | ZNF692 (inferredBy_Orthology). |
| IL1B | transfac_pro__M05972 | ZNF701 (directAnnotation). |
| Page: 1 2 |
Top |
Acts as a transcription factor |
| This table shows that this differential gene acts as a transcription factor. |
Top |
Acts as a drug target |
| This table shows that this differential gene acts as a drug target. |
| Target name | Drug name | Drug ID | Drug type |
| IL1B | "Andrographolide" | DB05767 | small molecule |
| IL1B | "Binimetinib" | DB11967 | small molecule |
| IL1B | "Canakinumab" | DB06168 | biotech |
| IL1B | "Dilmapimod" | DB12140 | small molecule |
| IL1B | "Donepezil" | DB00843 | small molecule |
| IL1B | "Etiprednol dicloacetate" | DB05442 | small molecule |
| IL1B | "Foreskin keratinocyte (neonatal)" | DB10772 | biotech |
| IL1B | "Gallium nitrate" | DB05260 | small molecule |
| IL1B | "Gevokizumab" | DB12119 | biotech |
| IL1B | "Minocycline" | DB01017 | small molecule |
| IL1B | "Rilonacept" | DB06372 | biotech |
| IL1B | "Talmapimod" | DB05412 | small molecule |
| IL1B | "VP025" | DB05133 | small molecule |
| IL1B | "VX-702" | DB05470 | small molecule |
| IL1B | "VX-765" | DB05507 | small molecule |
| Page: 1 |
| 1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
| 2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |
| 1 | Drug Repurposing to Treat Glucocorticoid Resistance in Asthma |
| 2 | Aldo-keto reductase 1C1 induced by interleukin-1Beta mediates the invasive potential and drug resistance of metastatic bladder cancer cells |
| 3 | Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study |
| 4 | Anakinra for severe forms of COVID-19: a cohort study Lancet Rheumatol |
Copyright 2022-Present -The University of Texas Health Science Center at Houston |